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Summary
Protease-activated receptors (PARs) are a unique
class of G protein-coupled receptors that play critical
roles in thrombosis, inflammation, and vascular biol-
ogy. PAR1 is proposed to be involved in the invasive
and metastatic processes of various cancers. How-
ever, the protease responsible for activating the pro-
invasive functions of PAR1 remains to be identified.
Here, we show that expression of PAR1 is both re-
quired and sufficient to promote growth and invasion
of breast carcinoma cells in a xenograft model. Further,
we show that the matrix metalloprotease, MMP-1, func-
tions as a protease agonist of PAR1 cleaving the re-
ceptor at the proper site to generate PAR1-dependent
Ca2+ signals and migration. MMP-1 activity is derived
from fibroblasts and is absent from the breast cancer
cells. These results demonstrate that MMP-1 in the
stromal-tumor microenvironment can alter the beha-
vior of cancer cells through PAR1 to promote cell mi-
gration and invasion.
Introduction
Protease-activated receptors (PARs) are tethered-ligand
receptors that are activated by proteolytic cleavage of
their extracellular domains. Four different PARs have
been identified: PAR1, PAR2, PAR3, and PAR4 (Cough-
lin, 2000). PAR1, the prototypic member of the PAR
family, has been shown to respond to a highly select
group of serine proteases that include thrombin (Vu et
al., 1991), plasmin (Kuliopulos et al., 1999), Xa (Riewald
et al., 2001), and activated protein C (Riewald et al.,
2002). Proteolytic cleavage exposes a new N terminus
that binds to the body of the receptor to induce trans-
membrane signaling to internally located G proteins
(Seeley et al., 2003). The activated G proteins in turn
trigger a cascade of downstream events, leading to di-
verse cellular outcomes such as calcium signaling, en-
gagement of integrins, cell adhesion and migration,
gene transcription, and mitogenesis.
An emerging common theme is that the PARs act as
high-gain sensors of extracellular protease gradients*Correspondence: athan.kuliopulos@tufts.eduand allow the cell to react to the proteolytically-altered
environment. This unique ability to sense proteases can
be utilized both for migration toward proteases and for
detection of a changing microenvironment (Kamath et
al., 2001). More recently, the PARs have been shown to
be critically involved in the tissue remodeling pro-
cesses necessary for normal development including
angiogenesis and trophoblastic invasion (Even-Ram et
al., 1998; Tsopanoglou and Maragoudakis, 1999; Griffin
et al., 2001; Even-Ram et al., 2003; Caunt et al., 2003).
Stimulation of PAR1 in atherosclerotic plaques has
been implicated in smooth muscle cell proliferation and
restenosis and in the response and repair processes of
a variety of acute and chronic inflammatory conditions
(Nelken et al., 1992).
Beyond its roles in vascular biology and tissue re-
modeling, PAR1 was identified as an oncogene by its
ability to transform NIH-3T3 cells (Whitehead et al.,
1995) via Rho pathways (Martin et al., 2001). Ectopic
expression of PAR1 in mammary gland epithelia exhib-
its an oncogenic phenotype of enhanced ductal com-
plexity in mice (Yin et al., 2003). PAR1 has long been
proposed to be involved in the invasive and metastatic
processes of cancers of the breast, colon, lung, pan-
creas, prostate, and melanoma (Nierodzik et al., 1992,
1998; Fischer et al., 1995; Even-Ram et al., 1998, 2001;
Zain et al., 2000). Even-Ram et al. (1998) demonstrated
that PAR1 expression levels were directly correlated
with degree of invasiveness in both primary breast tis-
sue specimens and established cancer cell lines. High
levels of PAR1 mRNA were found in infiltrating ductal
carcinoma and undetectable levels in normal and pre-
malignant hyperplasia. Recent studies by our group
(Kamath et al., 2001) showed that the invasive MDA-
MB-231 breast cancer cell line expresses very high
levels of functional PAR1, PAR2, and PAR4, whereas
minimally invasive MCF-7 cells have no PAR1 and low
levels of PAR2 and PAR4. Despite the necessity for the
presence of functional PAR1 on the cell surface (Even-
Ram et al., 1998), neither thrombin nor other serine pro-
teases were shown to be involved in PAR1-dependent
breast cancer cell motility, and at high concentrations,
thrombin could actually inhibit breast cancer cell inva-
sion (Kamath et al., 2001). Moreover, Zain et al. (2000)
had previously shown that thrombin has a bimodal ef-
fect on PAR1-dependent growth of melanoma, colon,
and prostate carcinomas. Low thrombin concentrations
enhance the growth of these cancer cells, whereas high
thrombin impairs growth and induces apoptosis. There-
fore, a critical issue to be addressed is whether a non-
serine protease found in the tumor environment is re-
sponsible for the proinvasive properties of PAR1 in the
cancer cells.
The most abundant class of nonserine proteases pre-
sent in invasive and metastatic tumors are the zinc-
dependent matrix metalloproteases (MMPs). MMPs are
used by invasive cancer cells to hydrolyze the struc-
tural proteins that comprise the extracellular matrix
such as collagen, elastin, laminin, fibronectin, vitronec-
tin, and fibrinogen (Sternlicht and Werb, 2001). Host
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304stromal cells also respond to nearby tumor cells by the P
sinduction of MMPs (Nelson et al., 2000). Immunohisto-
slogical examination of human tumor sections revealed
mthat MMPs are largely expressed by the stromal fibro-
tblast and inflammatory cells recruited to the tumor
N(Heppner et al., 1996).
tHere, we show that expression of PAR1 in breast car-
gcinoma cells is sufficient to promote growth and inva-
rsion of xenografts in nude mice. We demonstrate that
sthe presence of functional PAR1 accounts for the ma-
njority of the invasive signal in breast cancer cells. We
ridentify the matrix metalloprotease, MMP-1, to be a
7novel protease agonist that cleaves PAR1 at the proper
msite for receptor activation and generates PAR1-depen-
Pdent Ca2+ signals and migration. Targeting PAR1 with
mcell-penetrating pepducins can block the pathway
1downstream of MMP-1 and receptor, inhibiting angio-
rgenesis and cancer growth and invasion.
j
Results
w
sThe Presence of Functional PAR1 Confers
eIncreased Invasion in Breast Cancer Cells
SPrevious studies by our group (Kamath et al., 2001) and
aothers (Even-Ram et al., 1998) established a correlation
fbetween PAR1 expression levels and basal migration of
dbreast cancer cell lines toward conditioned media from
oNIH-3T3 fibroblasts. We first tested whether the presence
tof PAR1 is sufficient to confer migration and invasion
dof breast cancer cells that are normally noninvasive. A
PPAR1 null breast carcinoma cell line, MCF-7, which has
ca very low migration index (Kamath et al., 2001), was trans-
ifected with either vector alone (pcDEF3) or pcDEF3-
dPAR1. MCF-7 cells transiently expressing PAR1 exhib-
tited a 3.6-fold increase in migration (Figure 1A) and a
n4.3-fold increase in invasion (Figure 1B) through matri-
pgel as compared to their pcDEF3-transfected counter-
Tparts. Because simple overexpression of GPCRs can
tpromote constitutive activation of G protein signaling
pathways in the absence of agonist, we tested whether
e
a proteolytically dead PAR1 mutant receptor could also
o
confer promigratory behavior to the MCF-7 cells. PAR1
t
was rendered nonactivatable upon proteolytic cleavage M
by mutating the tethered ligand residue Phe-43 to ala- p
nine. The F43A PAR1 mutant does not transduce a sig- s
nal to internally located G protein following proteolytic h
cleavage of the R41-S42 bond but fully activates G pro- w
tein upon addition of exogenous peptide ligand such e
as SFLLRN or TFLLRN. As shown in Figures 1A and 1B, n
transfection of MCF-7 cells with F43A PAR1 promoted g
neither cell migration nor invasion, supporting the hy- 2
pothesis that PAR1 must be able to be activated for b
PAR1-dependent migration and invasion to occur. w
t
PAR1 Promotes Tumor Growth and Invasion s
in Nude Mice M
Next, we tested whether the proinvasive phenotype w
conferred by PAR1 in MCF-7 cells under in vitro condi- f
tions could be extended to an in vivo tumor model sys- F
tem. MCF-7 cells are thought to represent an early s
breast cancer phenotype because they are estrogen- p
sensitive and require transfection with oncogenes or in- t
tvasogenic factors to become tumorigenic in nude mice.AR1 was stably transfected into MCF-7 cells and as-
essed for the ability to confer tumor growth and inva-
ion in an orthotopic mammary fat pad model in nude
ice. Stable MCF7-PAR1 clones were isolated and
ested for PAR1 surface expression by FACS. Clone
55 was found to express high levels of PAR1, similar
o MDA-MB-231 cells (Kamath et al., 2001), and mi-
rated 16-fold and invaded 30-fold faster through mat-
igel relative to the parental MCF-7 cells (data not
hown). MCF7-PAR1/N55 and the MCF-7 control (PAR1
ull) parental cell line were injected into the left and
ight mammary fat pads, respectively, of female 6- to
-week-old athymic NCR nu/nu mice (Figure 1C). Tu-
ors developed only in mice injected with MCF7-
AR1/N55 (9/9), and there was no detectable tumor for-
ation with MCF-7 cells (0/10) within 8 weeks (Figure
D). MCF7-PAR1/N55 tumors grew exponentially in size
anging between 117–268 mm3 at 6 weeks after in-
ection.
Tumors were excised from the mammary pads 4–10
eeks postinoculation, and hematoxylin and eosin
taining of the MCF7-PAR1/N55 breast tumors revealed
xtensive replacement of normal mammary tissue (see
upplemental Figure S1A in the supplemental data
vailable with this article online). MCF7-PAR/N55 cells
ormed tumors that were tightly cohesive with poorly
ifferentiated, pleomorphic ductal carcinoma morphol-
gy and no recognizable glandular pattern. By 4 weeks,
he MCF7-PAR/N55 tumor cells had attached to the ab-
ominal muscle layer. At the 6 week time period, MCF7-
AR1/N55 cells had invaded the adjacent structures in-
luding the mammary fat tissue and at 10 weeks had
nvaded throughout the peritoneal cavity and into the
iaphragm (Supplemental Figure S1A). In contrast,
here was no detectable tumor formation by the PAR1
ull MCF-7 cells, and mammary pads had normal mor-
hology consisting of adipocytes and breast ductules.
hese data clearly demonstrate that PAR1 can promote
umor growth and invasion in nude mice.
The highly tumorigenic MDA-MB-231 cell line (Kang
t al., 2003), which constitutively expresses high levels
f PAR1 (Kamath et al., 2001), was also injected into
he murine mammary fat pads. Contrary to MCF-7, the
DA-MB-231 cells are estrogen receptor negative and
rovide a model for more aggressive, tamoxifen-insen-
itive, breast cancers. MDA-MB-231 cells also have en-
anced expression of many genes that are associated
ith poor outcome in breast cancer patients (van’t Veer
t al., 2002) and are more likely to form metastases in
ude mice models (Kang et al., 2003). Indeed, xeno-
rafts formed by MDA-MB-231 (10/10) grew more than
-fold faster relative to the N55 cells and had already
egun to invade into the abdominal muscle wall by
eek 6 (Figure 1D and Supplemental Figure S1A). We
hen tested whether knockdown of PAR1 gene expres-
ion would affect the mobility of the more invasive
DA-MB-231 breast cancer cells. MDA-MB-231 cells
ere treated for 48 hr with PAR1 siRNA, then PAR1 sur-
ace expression was assessed by FACS. As shown in
igure 1E, treatment of MDA-MB-231 cells with PAR1
iRNA caused an 80% decrease in median surface ex-
ression of PAR1 relative to control (luciferase) siRNA-
reated cells. The PAR1 siRNA treatment did not per-
urb surface expression of the PAR4 receptor present
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305Figure 1. PAR1 Is an Invasogenic Factor in
Breast Cancer Cells
(A) Migration of MCF-7 cells transiently trans-
fected with either wt PAR1, a PAR1 mutant
(F43A) with a deficient tethered ligand, or
vector alone (pcDEF3). MCF-7 cells (50,000)
were seeded onto an 8 µm pore membrane
in the upper well of a transwell apparatus
and allowed to migrate for 5 hr toward con-
ditioned media from NIH-3T3 fibroblasts.
Cells that migrated to the lower side of the
membrane were counted as described in the
Experimental Procedures.
(B) Invasion of transiently transfected MCF-7
cells through 10 µg matrigel per well using
NIH-3T3 medium as the chemoattractant
source in the bottom well.
(C) Tumor formation of MCF-7 cells (PAR1
null) versus MCF-7 cells stably expressing
PAR1 (MCF7-PAR1/N55) inoculated into mam-
mary fat pads of NCR nu/nu mice. Represen-
tative tumors shown are from the fourth
week postinoculation.
(D) Tumorigenicity of MCF7-PAR1/N55 and
MDA-MB-231 breast cancer xenografts.
(E) Silencing of PAR1 expression in MDA-
MB-231 cells with PAR1 siRNA versus firefly
luciferase siRNA control. Surface expression
of PAR1 and PAR4 after 48 hr treatment with
siRNA was determined by flow cytometry.
Gray traces: secondary antibody alone,
Black traces: primary plus secondary anti-
bodies.
(F) Effect of PAR1 siRNA transfection (48 hr)
on migration of MDA-MB-231 cells (50,000)
toward NIH-3T3 media.
(G) Effect of PAR1 siRNA transfection (48 hr)
on invasion of MDA-MB-231 cells (25,000)
through matrigel.on MDA-MB-231 breast cancer cells. Next, we deter-
mined the effect of loss of PAR1 expression on the abil-
ity of the MDA-MB-231 cells to migrate and invade to-
ward NIH-3T3 medium. As shown in Figures 1F and 1G,
the PAR1-siRNA-treated MDA-MB-231 cells migrated
70% less and invaded 60% less through matrigel rela-
tive to the control siRNA-transfected counterparts. This
60%–70% loss in migration and invasion as a conse-
quence of the 80% inhibition of PAR1 surface expres-
sion suggests that PAR1 may be responsible for the
majority of the migratory ability of the MDA-MB-231
cells toward NIH-3T3 media. To provide evidence that
the decreased migration response following PAR1 gene
silencing is specific to PAR1-mediated events, we
tested the effect of PAR1 siRNA treatment on migration
toward IL-8, a chemotactic ligand for the CXCR1/2 re-
ceptors on MDA-MB-231 cells (Muller et al., 2001). As
expected, migration of the MDA-MB-231 cells towardIL-8 was unaffected by the siRNA knockdown of PAR1
relative to untreated control cells (Supplemental Fig-
ure S1B).
Matrix Metalloproteases from Fibroblast Media
Are Responsible for the Majority of Migration
of MDA-MB-231 Breast Cancer Cells
We next sought to determine whether a protease was
in fact activating PAR1 and if so, determine the origin of
the protease. To address these questions, conditioned
medium was prepared from MDA-MB-231 breast can-
cer cells, NIH-3T3 (murine) immortalized fibroblasts, or
CRL-2076 (human) primary fibroblasts. Interestingly,
MDA-MB-231 cells migrated about half as well toward
their own media as compared to media from the fibro-
blasts (Figure 2). A panel of protease inhibitors was
then assessed for ability to block migration of the MDA-
MB-231 cells. Hirudin, a specific thrombin inhibitor, did
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PFigure 2. Fibroblast-Derived MMPs Induce Breast Cancer Cell Mi-
gration e
Migration of MDA-MB-231 breast cancer cells toward either RPMI- 5
1640 (−) or conditioned medium (CM) prepared from primary human h
CRL-2076 fibroblasts, NIH-3T3 fibroblasts, or MDA-MB-231 cells. b
The CM was supplemented with the protease inhibitors hirudin
(0.015 U), PMSF (100 µM), 1,10-phenanthroline (100 µM + 250 µM
PCaCl2), MMP-200 (200 nM), or vehicle alone (0.2% DMSO).
M
e
anot inhibit migration toward any of the media, consis-
itent with previous observations (Kamath et al., 2001).
pLikewise, addition of the serine protease inhibitor,
MPMSF, to the media in the bottom well of the chemotac-
btic chambers had no effect on mobility of the MDA-MB-
I231 cells. These results militate against the direct or
nindirect participation of serine proteases or thrombin in
tthe migration of the breast cancer cells toward fibro-
tblast or MDA-MB-231 media.
bWe then turned our attention to another class of pro-
3teases which are highly abundant in tumors—namely
othe Zn2+-dependent matrix metalloproteases. Two broad-
gspectrum inhibitors of MMPs were employed: 1,10 phe-
dnanthroline, a divalent cation-chelating agent, and
bMMP-200, a hydroxyamate inhibitor of MMPs. Strik-
iingly, the MMP inhibitors reduced the migration of
MDA-MB-231 cells toward the fibroblast-derived media
by two-thirds (Figure 2). In contrast, the MMP inhibitors A
odid not significantly reduce the migration of MDA-MB-
231 cells toward their own medium. Therefore, our data P
eindicate that the MMPs derived from the MDA-MB-231
cancer cells themselves are not sufficient for cell migra- c
vtion. In these in vitro assays, PAR1-dependent migra-
tion does not require proteolysis of extracellular matrix; t
ptherefore, MMP involvement cannot be attributed to
matrix digestion but can be assigned to induction of M
cpromigratory signaling pathways in the cells. We hy-
pothesized that MMPs secreted from the fibroblasts (
iwere responsible for PAR1 activation and breast cancer
cell migration. l
(
rPAR1 Activation Induces Promigratory Signaling
in MDA-MB-231 Breast Cancer Cells i
bThe MDA-MB-231 cells were treated with a panel of
PAR1 antagonists in order to correlate the effects of
sPAR1 siRNA knockdown with pharmacologic blockade
of PAR1. The BMS-200261 and RWJ-56110 compounds cre small molecule ligand-based antagonists (Berna-
owicz et al., 1996; Andrade-Gordon et al., 1999) that
lock intramolecular activation of PAR1 by proteolyti-
ally generated tethered ligand (Seeley et al., 2003). As
hown in Figure 3A, the RWJ-56110 and BMS-200261
ompounds blocked up to 57% of the migration of
DA-MB-231 cells toward fibroblast media.
We also determined whether cell-penetrating pep-
ucin antagonists of PAR1 (Covic et al., 2002a; Covic
t al., 2002b) could inhibit migration of the MDA-MB-
31 cells. The P1pal-12 pepducin is a palmitoylated
eptide based on the N-terminal portion of the third
ntracellular loop (i3) of PAR1 that can interdict signal-
ng between PAR1 and intracellular G proteins. In addi-
ion, we tested a C-terminal i3 loop pepducin, P1pal-7,
hich is a full antagonist of PAR1-G protein signaling
Supplemental Figure S2). As shown in Figure 3A, the
1pal-12 and P1pal-7 pepducins gave similar inhibitory
ffects as the extracellular PAR1 antagonists RWJ-
6110 and BMS-200261 and blocked approximately
alf of the migration of MDA-MB-231 cells toward fibro-
last media.
To further demonstrate that proteolytic activation of
AR1 is capable of stimulating migration of the MDA-
B-231 breast cancer cell line, we inhibited the endog-
nous MMPs present in the media with MMP-200 and
dded low concentrations of exogenous thrombin. If it
s true that proteolytic activation of PAR1 by an MMP
resent in the media induces migration, then preventing
MP cleavage of PAR1 should allow activation of PAR1
y exogenous thrombin and recovery of full migration.
ndeed, we showed that low concentrations of exoge-
ous thrombin (10–500 pM) can induce full migration of
he MDA-MB-231 breast cancer cells. Thrombin induc-
ion of MDA-MB-231 cell motility was completely
locked by the BMS-200261 PAR1 antagonist (Figure
B), thereby demonstrating that the effect of thrombin
n the MDA-MB-231 cells was PAR1 dependent. To-
ether, these data suggest that PAR1 activation in-
uced by MMP(s) present in the fibroblast media can
e mimicked by exogenous thrombin to cause a major
ncrease in migration of breast cancer cells.
bility of Individual MMPs to Affect Migration
f MDA-MB-231 Breast Cancer Cells
ure MMPs were tested individually to determine their
ffects on migration of MDA-MB-231 breast cancer
ells. Commercially available pro-MMPs were first acti-
ated with aminophenylmercuric acetate (APMA) and
hen dialyzed to remove the cytotoxic mercury com-
ound. The active form of the MMP was then added to
DA-MB-231 medium placed in the lower well of the
hemotactic chamber. Of the MMPs that were tested
MMP-1, -2, -3, -7, and -9), only MMP-1 was able to
nduce an increase in migration that was nearly equiva-
ent to full migration toward fibroblast-derived media
Figure 4A). Addition of 5 nM MMP-1 to RPMI-1640 se-
um-free media in the bottom well also induced a signif-
cant increase in migration which was completely blocked
y the PAR1 antagonist BMS-200261 (Figure 4B).
We knocked down gene expression of PAR1 with
iRNA and confirmed that MMP-1 could not act as a
hemotactic agent for MDA-MB-231 cells in the ab-
MMP-1 Activation of PAR1 in Cancer Cell Invasion
307Figure 3. Effect of Inhibition or Stimulation of
PAR1 on Migration of MDA-MB-231 Cells
(A) MDA-MB-231 cells migration toward NIH-
3T3 CM supplemented with PAR1 antago-
nists based on either the extracellular ligand
(RWJ-56110, BMS-200261) or cell-penetrat-
ing pepducins derived from the third intra-
cellular loop of PAR1 (P1pal-12, P1pal-7).
(B) MDA-MB-231 cells migration toward NIH-
3T3 CM supplemented with 0–500 pM
thrombin in the presence of either MMP-200
(200 nM), BMS-200261 (100 µM), or 0.2%
DMSO vehicle (open circle).ward NIH-3T3 media. Together, these data demonstratein cell migration. Simultaneous immunodepletion of
Figure 4. Fibroblast MMP-1 Mediates PAR1-
Dependent Migration of Breast Cancer Cells
(A) MDA-MB-231 cell migration toward MDA-
MB-231 CM in the presence of 5 nM of
APMA-activated MMP-1, MMP-2, MMP-3,
MMP-7, MMP-9, or dialysis buffer alone.
(B) MDA-MB-231 migration toward RPMI-
1640/0.1% BSA in the presence or absence
of MMP-1 and/or the PAR1 antagonist BMS-
200261.
(C) MDA-MB-231 cells were treated for 48 hr
with PAR1 siRNA or luciferase siRNA control
(−) and allowed to migrate toward MDA-MB-
231 CM in the presence or absence of
MMP-1.
(D) MDA-MB-231 cell migration toward CRL-
2076 CM that was immunodepleted for indi-
vidual MMPs. Monoclonal antibodies against
the indicated MMPs or IgG control were cou-
pled to Protein A Sepharose beads and used
to immunodeplete CRL-2076 CM. The immu-
nodepleted media served as chemoattrac-
tant in a standard migration assay.
(E) MDA-MB-231 cell migration toward NIH-
3T3 CM that was supplemented with selective
MMP inhibitors used at concentrations R3-
fold above relevant IC50: 3 M MMP Inh-1
(IC50 = 1 M [MMP-1], 30 M [MMP-3], 1 M
[MMP-8], 150 M [MMP-9]), 5 M MMP2-Inh
(IC50 = 1.7 M [MMP-2]), 50 M MMP2/3-Inh
(IC50 = 17 M [MMP-2], 150 nM [MMP-3]).
# p < 0.05, * p < 0.01.sence of PAR1. As shown in Figure 4C, pretreatment of
MDA-MB-231 cells with PAR1 siRNA completely blocked
MMP1-induced chemotaxis of MDA-MB-231 cells, in-
dependently demonstrating that the chemotactic ef-
fects of MMP-1 require PAR1. In the converse experi-
ment, we immunodepleted individual MMPs from
human CRL-2076 fibroblast media with the correspond-
ing anti-human MMP antibodies coupled to beads. As
shown in Figure 4D, immunodepletion of MMP-1 from
CRL-2076 media caused a 45% drop in cell migration
which accounted for all of the MMP-200-sensitive ac-
tivity. Treatment of the CRL-2076 media with antibodies
directed against MMP-2 or MMP-9 gave slight dropsMMP-1 and MMP-2 gave the same drop in chemotaxis
as immunodepletion of MMP-1 alone. No effects were
seen upon treatment with anti-MMP-3 or -7 antibodies.
The effect of selective pharmacologic blockade of
MMP-1 on cell migration toward NIH-3T3 media was
also tested. Three different MMP inhibitors with varying
selectivity to MMP-1, MMP-2, and MMP-3 were added
to the media in the bottom well. The tetrapeptidyl hy-
droxamic acid, MMP Inh-1 (FN-439), which targets
MMP-1 but not MMP-2 or MMP-3 (Odake et al., 1994),
blocked 75% of migration. In contrast, MMP2-Inh
(blocks MMP-2) and MMP2/3-Inh (blocks MMP-2 and
MMP-3) had no effect on migration of MDA-MB-231 to-
Cell
308that MMP-1 is capable of inducing PAR1-dependent p
omigration of MDA-MB-231 breast cancer cells and may
be responsible for most of the MMP chemotactic activ- s
oity in the fibroblast media.
f
oIdentification of MMP-1 in Media
from CRL-2076 Fibroblasts t
3Using RT-PCR, we confirmed that CRL-2076 fibroblasts
express mRNA encoding MMP-1 (Figure 5A). CRL-2076 c
tcells also express mRNA for MMP-2 and very low levels
of MMP-9 mRNA. ELISA and collagenase analyses indi- f
lcated that MMP-1 levels were 34 ± 8 ng/ml (0.6 ± 0.2
nM) and MMP-2 levels were 22 ± 9 ng/ml (0.3 ± 0.1 nM) M
din the CRL-2076 fibroblast media. Similarly, NIH-3T3
media contained 0.6–1.0 nM MMP-1 collagenase activ- t
Aity. As expected, MDA-MB-231 cells do not have mRNA
encoding MMP-1 but do express low levels of MMP-2 w
imRNA and higher levels of MMP-9 mRNA. The MDA-
MB-231 cells did not secrete detectable levels (<0.1 ng/ c
cml) of pro- or active forms of MMP-1 or MMP-2. To-
gether, these data are consistent with other reports l
(which show that MDA-MB-231 cells do not normally
express MMP-1 or MMP-2 (Kang et al., 2003). 1
tExtensive studies have shown that breast cancer
cells can also migrate toward a variety of small chemo-
kines (0.5–10 kDa) which are abundant in tumor speci- M
Amens (Youngs et al., 1997; Muller et al., 2001). We next
sought to separate the MMP chemotactic activity from C
Pthe other chemokines potentially secreted by the fibro-
blasts. Conditioned medium containing fetal bovine se- d
Srum proved to be exceedingly difficult to fractionate
due to the high concentration of albumin. Therefore, we 1
oprepared medium from the CRL-2076 fibroblasts underFigure 5. Primary Human CRL-2076 Fibroblasts Secrete MMP-1 into Their Media
(A) CRL-2076 fibroblasts but not MDA-MB-231 breast cancer cells express MMP-1 mRNA. Total RNA was extracted from CRL-2076 or MDA-
MB-231 cells. cDNA was prepared and portions of the cDNA corresponding to MMP-1, MMP-2, MMP-9 or b-actin messages were amplified
by reverse transcriptase PCR and separated on a 1.5% agarose gel.
(B) Serum-free CRL-2076 CM was concentrated 20-fold and 200 µl applied onto a Superose-12 column equilibrated with TBS at 4°C. MMP-1
concentration (mean ± 1 SD; n = 3) was determined in 1 ml fractions by Quantikine ELISA (R&D Systems, Minneapolis). Chemotactic activity
of each fraction (dashed line) was determined in duplicate using a standard MDA-MB-231 cell migration assay. This fractionation experiment
was repeated three times and gave similar results.serum-free culture conditions. This serum-free mediaossessed 85% of the chemoattractive activity of the
riginal CRL-2076 medium for MDA-MB-231 cells. The
erum-free CRL-2076 medium was fractionated by size
ver a Superose-12 gel-filtration column. Individual
ractions were assayed for ability to promote migration
f the MDA-MB-231 cells. We found that the promigra-
ory activity separated into a major peak (fractions
–6) and a minor peak (fractions 13–18) (Figure 5B). The
hemotactic activity of fractions 3–6 peaked at a rela-
ive molecular mass of 55 kDa and together accounted
or 55% of the total chemoattractive activity of the
oaded material and was blocked by the MMP inhibitor
MP-200 (data not shown). ELISA assays were con-
ucted in order to confirm that MMP-1 was present in
he higher molecular mass peak of chemotactic activity.
s shown in Figure 5B, MMP-1 eluted at fraction 6,
hich contained the highest level of chemotactic activ-
ty. The small-molecular-mass (<10 kDa) fractions 13–18
ontributed to 34% of the total chemotactic activity—in
lose agreement with the residual chemotactic activity
eft after treatment of CRL-2076 media with MMP-200
Figure 2). Thus, the chemotactic activity in fractions
3–18 likely represents small chemokines secreted by
he fibroblasts, though this remains to be determined.
MP-1 Cleaves PAR1 at the Proper Site for Receptor
ctivation and Generates PAR1-Dependent
a2+ Signals in Breast Cancer Cells
AR1 is activated by proteolytic cleavage between resi-
ues R41 and S42 which creates a new N terminus,
42FLLRN, that acts as a tethered ligand (Vu et al.,
991; Seeley et al., 2003). To demonstrate that MMP-1
r other MMPs can directly cleave PAR1 at this site,we placed a T7 epitope to the N-terminal side of the
MMP-1 Activation of PAR1 in Cancer Cell Invasion
309R41-S42 site and expressed the T7-tagged PAR1 in
COS7 cells. Cleavage of PAR1 at the R41-S42 peptide
bond by the MMP would result in loss of the T7 epitope
but retention of the SFLLRN epitope (Figure 6A). In-
deed, we demonstrated that treatment of the COS7
cells with 5 nM MMP-1 resulted in 50% loss of the T7-
epitope while leaving the SFLLRN epitope intact. Simi-
larly, treatment of the T7-PAR1 COS7 cells with 0.5 nM
thrombin caused 55% loss of the T7 epitope with reten-
tion of the SFLLRN epitope. Treatment with NIH-3T3
media caused 30% loss of the T7 epitope, similar to
0.25 nM thrombin. In contrast, 5 nM concentrations of
MMP-2, MMP-3, MMP-7, and MMP-9 gave little cleav-
age of COS7-expressed T7-PAR1 either to the N- or
C-terminal side of the SFLLRN epitope (Figure 6A).
These cleavage experiments demonstrate that PAR1 is
cleaved at the appropriate site by MMP-1 but is not
readily cleaved by MMP-2, -3, -7, or -9.
To directly elicit a functional MMP-1-dependent
PAR1 response on the surface of breast cancer cells,
we conducted Ca2+ flux measurements of the MCF7-
PAR1/N55 cells. Addition of 5 nM MMP-1 to N55 cells
gave 50% of the Ca2+ peak height relative to 0.5 nM
thrombin but gave a similar total integrated (area) Ca2+
response (Figure 6B). Challenge of the N55 cells with
15 nM MMP-1 gave a robust Ca2+ response that was
completely blocked by the PAR1-selective antagonist
RWJ-56110. None of the other MMPs that were tested
(15 nM MMP-2, MMP-3, MMP-7, MMP-8, or MMP-9)
were able to elicit a Ca2+ signal from the N55 cells.
The Therapeutic Potential of Targeting PAR1
versus MMP-1 on the Growth and
Angiogenesis of Breast Tumors
We have demonstrated that the presence of PAR1 pro-Figure 6. MMP-1 Directly Cleaves PAR1 and Generates PAR1-Dependent Ca2+ Signals in Breast Cancer Cells
(A) COS7 cells were transiently transfected with T7-tagged PAR1 incubated with thrombin (T), NIH-3T3 media, or the indicated matrix metallo-
proteases for 30 min at 37°C. Loss of T7 and SFLLRN epitopes over time (mean ± 1 SD; n = 3) were analyzed by flow cytometry as described
(Kuliopulos et al., 1999).
(B) Calcium-flux measurements of MCF7-PAR1/N55 cells following challenge with MMPs or thrombin (T) were performed at 25°C with emission
recorded at 510 nm with dual excitation at 340 and 380 nm as described (Kuliopulos et al., 1999).motes tumor growth and invasion; however, we havenot yet shown that MMP-1 is also necessary for the
tumorigenicity of PAR1-expressing breast cancer cells
in vivo. To examine the contribution of MMP-1 to the
tumorigenicity of the MCF7-PAR1/N55 cells, we first
determined whether the MMP-1 levels were elevated in
the N55 tumors relative to control mammary pads. N55
tumors were harvested from untreated mice at week 6
and examined for MMP-1 mRNA expression and colla-
genase activity. As shown in Figure 7A, murine MMP-1
mRNA was induced 2-fold relative to control mammary
fat pads. Collagenase activity was enhanced 4-fold in
the N55 tumors relative to mammary fat pads (Figure 7B).
The collagenase activity in the N55 tumors was inhibited
by 50% upon addition of the selective MMP-1 antago-
nist, MMP Inh-1 (Odake et al., 1994), with no effect on
the collagenase activity in the control fat pads, which
demonstrates that MMP-1 expression and MMP-1 col-
lagenase activity are enhanced in the PAR1-expressing
N55 breast tumors.
To provide direct evidence that MMP-1 was essential
for the tumorigenicity of the PAR1-dependent tumors,
we compared the effects of pharmacologic blockade of
PAR1 versus MMP-1 on the growth of the N55 breast
cancer xenografts. To block PAR1, we used the cell-
penetrating i3 loop PAR1 pepducin antagonist, P1pal-7.
MCF7-PAR1/N55 cells were injected into the mammary
fat pads and the mice treated two days later (to allow
implantation) with either vehicle or P1pal-7 (10 mg/kg
s.c. every other day) for 6 weeks. As shown Figure 7C,
by the 6 week time point, P1pal-7 significantly inhibited
(62%) the growth of the MCF7-PAR1/N55 xenografts.
The P1pal-7 pepducin treatment was well tolerated by
the mice with no observable toxicity. We then treated
the mice with MMP Inh-1 for 6 weeks and measured
tumor growth. Quite strikingly, MMP Inh-1 treatment of
the N55 mice gave 82% inhibition of tumor growth (Fig-
Cell
310Figure 7. Treatment of Nude Mice with a Cell-
Penetrating Pepducin Targeted against PAR1
or an MMP-1 Antagonist Inhibits Growth of
Breast Cancer Xenografts
(A) MCF7-PAR1/N55 or MCF-7 cells (4 × 106)
were inoculated in the mammary fat pads of
NCR nu/nu mice and harvested at 6 weeks.
N55 breast tumors or MCF-7 control mam-
mary fat pads were flash frozen in liquid N2
and tissue disrupted as described in the Ex-
perimental Procedures. PCR primers were
used to amplify the murine MMP1A (Mcol-A)
transcript or actin control (mean ± 2 SEM;
n = 3).
(B) Collagenase activity of the MCF7-PAR1/
N55 xenografts or control mammary fat pads
(MFP) harvested at 6 weeks was conducted
as described in the Experimental Procedures.
Collagenase activity was determined in the
presence or absence of 5 M MMP Inh-1
(mean ± 2 SEM; n = 3).
(C) MCF7-PAR1/N55 cells (4 × 106) were in-
oculated into the mammary fat pads of NCR
nu/nu mice. Two days later, treatments (100
µl subcutaneously, every other day) were ini-
tiated: (1) vehicle alone (20% DMSO), (2) 10
mg/kg P1pal-7, or (3) 5 mg/kg MMP Inh-1.
Tumor volume was measured once weekly
using a digital caliper. The median tumor size ±
1 SD, n = 10 breast tumors, is indicated for
each data point. * p < 0.01.ure 7C) as compared to untreated control. In in vitro r
cassays, MMP Inh-1 did not nonspecifically block throm-
bin activity (data not shown). Therefore, these in vivo u
idata provide functional support for the involvement of
MMP-1 in the tumorigenesis of human breast cancer g
acells that express PAR1. These data also indicate that
thrombin does not dominate the system and is not able m
mto complement the defect of MMP-1 in the MMP Inh1-
treated mice. It still remains possible that MMP-1 plays r
aother roles beyond cleavage and activation of PAR1 in
these tumors. M
PLastly, we compared the morphology, invasive edge,
and degree of vascularization of the untreated (vehicle)
versus P1pal-7- and MMP Inh-1-treated N55 breast tu- D
mors harvested at the end of the experiment of Figure
7C. Hematoxylin and eosin staining showed that the T
tmorphology of the N55 tumors from all three groups
was similar to poorly differentiated invasive ductal car- c
hcinoma of human breast specimens. The xenografts
from the P1pal-7 and MMP Inh-1 treatment groups r
zgave a very similar infiltrating pattern of tumor growth
into the adjacent skeletal muscle (Supplemental Figure a
lS3). Immunohistochemical staining for endothelial cellsevealed prominent von Willebrand Factor-positive vas-
ular structures within the central tumor mass of the
ntreated group. In contrast, significantly less vascular-
ty was present in the Plpal-7- and MMP Inh-1-treated
roups (Supplemental Figure S3). Therefore, P1pal-7
nd MMP Inh-1 treatment have the same effects on tu-
or morphology, invasion, and vascularity. Further-
ore, these results are consistent with the proposed
ole of PAR1 in angiogenesis (Griffin et al., 2001; Yin et
l., 2003; Caunt et al., 2003) and provide evidence that
MP-1 may also promote angiogenesis by activating
AR1.
iscussion
he present study made the unanticipated discovery
hat PAR1 can be directly activated by the interstitial
ollagenase MMP-1. Although several serine proteases
ave been identified as PAR agonists, this is the first
eport that a PAR can be activated by a member of the
inc-dependent matrix metalloprotease family. PAR1
ctivation by MMP-1 provides a link between extracel-
ular proteolytic activity important for remodeling of the
MMP-1 Activation of PAR1 in Cancer Cell Invasion
311extracellular matrix with signaling leading to cell migra-
tion and invasion.
We also showed that PAR1 is a potent tumorigenic
and invasogenic factor for human MCF-7 breast cancer
cells in an orthotopic nude mouse model. PAR1 expres-
sion has been directly correlated with degree of inva-
siveness in both primary breast tissue specimens
(Even-Ram et al., 1998) and in established cancer cell
lines from humans (Nierodzik et al., 1998; Ross et al.,
2000). Similarly, MMP-1 has been shown to be a marker
of poor prognosis in breast, colorectal, and esophageal
tumors (Murray et al., 1998; van’t Veer et al., 2002).
As a new example of tumor-host interdependence,
we showed that the MMP-1 that was cleaving PAR1
was not produced by the breast cancer cells them-
selves but instead was secreted by the fibroblasts. In-
deed, overwhelming evidence suggests that MMPs
necessary for the invasion of cancer cells originate
mainly from stromal fibroblasts, myofibroblasts, inflam-
matory cells, and endothelium (Egeblad and Werb,
2002). Immunohistological examination of human tumor
sections revealed that MMP-1 and other MMPs are ex-
pressed by the stromal cells recruited to the tumor
(Heppner et al., 1996; Nelson et al., 2000). The tumor
cells secrete several factors including interleukins, cy-
tokines, and angiogenesis factors, to induce the host
stromal cells to produce MMPs (Zucker et al., 1998;
Nelson et al., 2000, Sternlicht and Werb, 2001). Conver-
sion of fibroblast-derived pro-MMP-1 to active MMP-1
by membrane-tethered or membrane-associated MMPs
may present high local concentrations of MMP-1 to
PAR1 on the same tumor cell surface.
We showed that the endogenous MMP-1 activity gen-
erated in situ from the fibroblast media cleaves PAR1 and
is sufficient to cause robust migration and invasion of
breast cancer cells via PAR1. Indeed, MMP-1 cleavage
of PAR1 compares favorably with factor Xa (Camerer et
al., 2000), plasmin (Kuliopulos et al., 1999), and acti-
vated protein C (APC) (Riewald et al., 2002) activation of
PAR1 relative to thrombin. To our knowledge, we have
provided the first demonstration of direct activation of
a G protein-coupled receptor by an MMP.
A biological rationale for our results is that the breast
cancer cells first utilize fibroblast-derived MMP-1 to ac-
tivate PAR-1 which promotes cell migration toward the
stroma and MMP-1 source. MMPs derived from the
cancer cell itself or adherent to the cancer cell may help
to catalyze activation of pro-MMP-1 and digest the
ECM at the invasion front and together with the MMP1-
PAR1 chemotactic signal allow the cell to invade into
the surrounding stromal tissues. During the later vascu-
lar invasive and metastatic stage when the cancer cells
acquire the ability to enter the blood stream, PAR1 may
be activated by the TF-thrombin system and help medi-
ate adhesion to the endothelium and underlying matrix
at distant metastatic sites, perhaps with the assistance
of adherent platelets (Nierodzik et al., 1992; Fischer et
al., 1995). It is possible that MMP-1 may also play a role
in the later metastatic phase of breast cancer pro-
gression. Interestingly, Kang et al. (2003) showed that
bone metastases originating from MDA-MB-231 fat pad
xenografts have enhanced MMP-1 expression. There-
fore, depending on the relative local concentrations of
MMP-1 and thrombin and the stage of tumor pro-gression, either protease could activate PAR1-depen-
dent signaling to cause the cancer cell to migrate, in-
vade, or adhere.
Another area where MMPs and PARs have both been
shown to play important roles is in inflammation and
atherosclerosis (Nelken et al., 1992; Libby and Aikawa,
2002). Increased expression of MMP-1 and other MMPs
occurs in the vulnerable shoulder and cap regions of
atherosclerotic plaques (Libby and Aikawa, 2002).
MMP-1, which is expressed in the macrophages, vas-
cular smooth muscle cells, and endothelium of athero-
matous plaques, is the most abundant MMP present
that can cleave the native collagen types I and III which
comprise the major tensile components of the fibrous
plaque cap (Libby and Aikawa, 2002). Therefore, it has
been suggested that MMP-1 may be partly responsible
for plaque rupture. Stimulation of PAR1 in atheroscler-
otic plaques has also been implicated in smooth mus-
cle cell proliferation and restenosis and exaggerated
vasoconstrictory response (Nelken et al., 1992; Ku and
Dai, 1997). It has been assumed that thrombin is the
agonist that is activating PAR1-dependent proinflam-
matory and proliferative signaling within the athero-
sclerotic plaque; perhaps MMP-1 may contribute to
PAR1 activation in the inflammatory lesion.
Finally, our results, together with the foregoing
studies, suggest that therapeutics that block MMP-1
may prove beneficial in the treatment of a variety of
invasive, proliferative, and inflammatory conditions.
However, numerous phase III clinical trials with broad-
spectrum MMP inhibitors for treatment of diverse can-
cers have suffered from dose-limiting joint toxicity
thought to be due to inhibition of MMP-1 (Nelson et
al., 2000; Yamamoto et al., 2002). Hence, PAR1, a new
receptor for MMP-1, becomes an attractive target as a
novel therapeutic approach, as exemplified by the
PAR1 pepducin P1pal-7, for blocking the progression
and angiogenesis of invasive and metastatic cancers
and in inflammatory conditions when it is not possible
to directly inhibit MMP-1.
Experimental Procedures
Reagents
Recombinant hirudin and purified human MMPs were obtained
through EMD Biosciences (San Diego, California). MMP-200 was
from Enzyme Systems Products (Livermore, California). MMP Inh-I,
MMP2-Inh, and MMP2/3-Inh were from Calbiochem (La Jolla, Cali-
fornia). BMS-200261 was synthesized by AnaSpec (San Jose, Cali-
fornia). N-palmitoylated peptides P1pal-12 and P1pal-7 were syn-
thesized by standard fmoc solid phase synthetic methods with
C-terminal amides as before (Covic et al., 2002a). Rabbit polyclonal
PAR1-Ab and PAR4-Ab were purified by peptide affinity chroma-
tography as described previously (Kuliopulos et al., 1999).
Molecular Biology
Construction of the genes encoding human PAR1 have been de-
scribed (Kuliopulos et al., 1999; Jacques and Kuliopulos, 2003). A
PAR1 mutant with a deficient tethered ligand, F43A, was con-
structed as described (Chen et al., 1994). All PAR1 constructs were
inserted into the mammalian expression vector pcDEF3, which
places PAR1 under the control of a human EF-1a promoter and
carries a neomycin selectable marker. Small interfering (si)-RNA di-
rected against PAR1 (5#-AAGGCUACUAUGCCUACUACU-3#), and
firefly luciferase (5#-CGTACGCGGAATACTTCGA-3#) were synthe-
sized by Dharmacon (Lafayette, Colorado). For rt-PCR, total RNA
was extracted from MDA-MB-231 and CRL-2076 cells with the
Cell
312Rneasy mini kit (Qiagen, Valencia, California). cDNA was prepared v
twith 5 µg of total RNA using MMLV reverse transcriptase. The de-
sired products were amplified with Taq polymerase and the w
sfollowing primers: hMMP-1 sense 5#-CGACTCTAGAAACACAAGA
GCAAGA-3#, antisense 5#-AAGGTTAGCTTACTGTCACA CGCTT-3#; A
thMMP-2 sense 5#-GTGCTGAAGGACACACTAAAGAAGA-3#, anti-
sense 5#-TTGCCATCCTTCTCAAAGTTGTAGG-3#; hMMP-9 sense
5#-CACTGTCCACCCCTCAGAGC-3#, antisense 5#-GCCACTTGTCG
GCGATAAGG-3#; mMMP-1 (Mcol-A) sense 5#-TCTTTATGGTCCA S
GGCGATGAA-3#, antisense 5#-CCTCTTCTATGAGGCGGGGATA-3#. S
a
Cell Culture D
MDA-MB-231 and MCF-7 cells (human breast carcinomas) were
obtained from the NCI (Frederick, Maryland). NIH-3T3 and CRL-
2076 fibroblasts were from the ATCC (Manassas, Virginia). MCF-7 A
cells were transfected using LipofectAMINE, and 20 µg of DNA
were used for each 100 mm tissue culture dish. MCF-7 cells stably T
expressing wt PAR1 such as clone N55 (MCF7-PAR1/N55) were S
first selected with 750 g/ml geneticin for one week and then re- H
trieved with magnetic Dynabeads (M450) coupled with the PAR1- a
Ab. MDA-MB-231 cells were transfected with OligofectAMINE A
using 20 µM siRNA oligo per 100 mm plate. p
a
Conditioned Media Preparation and Migration a
and Invasion Assays
MDA-MB-231, NIH-3T3, or CRL-2076 cells were growth to 50% con-
R
fluency. The media was then changed to fresh growth media and
R
cells were incubated for an additional 48 hr. The conditioned media
A
was drawn off the cells and centrifuged at 25°C for 5 min at 200 ×
P
g to remove debris and stored at −20°C. Invasion of cells through
matrigel was conducted using a Transwell apparatus (Corning
RCostar) as described previously (Kamath et al., 2001). Data is ex-
pressed as mean number of cells migrating ±1 SEM (n = 2–4).
A
AOrthotopic Mammary Fat Pad Model in Nude Mice
DThese experiments were conducted in full compliance with the
cTufts-NEMC Institutional Animal Care and Use Committee. Groups
lof five NCR nu/nu mice (Taconic Farms) each received two mam-
Bmary fat pad inoculations consisting of 4 × 106 MCF-7 and 4 × 106
NMCF7-PAR1/N55 human breast cancer cells. Tumors and surround-
cing tissue were excised from sacrificed mice, fixed in 10% formalin/
PBS, and imbedded in paraffin. Tissue sections (5 m) were pre- C
pared and stained with hematoxylin-eosin. a
2
MMP-1 Expression and Collagenase Activity C
Breast tumor xenografts or control mammary fat pads were ex- T
cised from nude mice, and tissue samples were lysed by freezing m
the tissue in liquid nitrogen, grinding the frozen tissue to a powder, C
and adding the powder to lysis buffer. The lysis buffer consisted of T
RNeasy lysis buffer (Qiagen) for RT-PCR and 10 mM Tris-HCl (pH
C7.4), 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.1% Triton X-100,
r100 M PMSF, 100 mM dithiothreitol, and 10 g/ml leupeptin for
Cthe collagenase assay. Collagenase activity was assayed in lysed
(tumor samples and in fibroblast media by measuring the cleavage
bof fluorescein conjugated DQ collagen (Molecular Probes). Colla-
Sgenase assays contained 10 g DQ collagen in 50 mM Tris-HCl (pH
7.6), 150 mM NaCl, 5 mM CaCl2, and 0.2 mM NaN3, and cleavage C
was monitored continuously over time by a fluorescence micro- P
plate reader at 538 nm (excitation at 485 nM) at 25°C. One unit of s
collagenase activity was defined as the cleavage of 1 g collagen E
per minute at 25°C. a
EActivation of pro-MMPs
MStock solutions of pro-MMPs containing 400 nM pro-MMPs were
Tactivated with 2 mM APMA in 50 mM Tris (pH 7.7), 5 mM CaCl2, i0.2 M NaCl, and 50 µM ZnCl2 at 37°C for 30 min and then transfer-
Ered to an ice bath prior to use. For migration assays, the APMA
wwas removed by overnight dialysis in 10 kDa MWCO Mini Slide-
iA-Lyzers (Pierce, Rockford, Illinois) at 4°C.
e
1Immunodepletion of MMPs
CRL-2076-conditioned medium was diluted 1:3 with 20 mM potas- E
Zsium phosphate buffer (pH 7.5), 150 mM NaCl (PBS) (1.3 ml finalolume), and 5 µg MMP-Ab or IgG control was added and the mix-
ure and gently rocked at 4°C for 2 hr. Antibody-antigen complexes
ere bound to Protein A beads (Pharmacia, Piscataway, New Jer-
ey) (130:5 v/v) by incubating for an additional 2 hr. The Protein
-antibody/antigen beads were removed from the medium by cen-
rifugation (300 × g for 5 min, 4°C).
upplemental Data
upplemental Data include three figures and can be found with this
rticle online at http://www.cell.com/cgi/content/full/120/3/303/
C1/.
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